Detailed price information for Anaptysbio Inc (ANAB-Q) from The Globe and Mail including charting and trades.

Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related ...

Last winter’s respiratory syncytial virus, or RSV, season wasn’t as brutal for U.S. babies. A new study suggests two preventive tools — a maternal vaccine and a monoclonal antibody for ...

For a broader group of infants—0 to 7 months old—RSV-NET showed a 43 percent drop in hospitalizations in the 2024–2025 RSV season, and NVSN saw a 28 percent drop.

RSV-associated hospitalizations for children aged 8-19 months or 20-59 months were not significantly different between the two time periods, and slightly higher in the 2024-2025 period.

Among infants aged 0 to 7 months, cumulative RSV-associated hospitalization rates were significantly lower in the 2024-2025 season (RSV-NET, 8.5 per 1000 children; NVSN, 10.7 per 1000 children ...

Saskatchewan is expanding its infant RSV immunization program to include all babies born one month before and during RSV season, which typically lasts from the start of October until the end of March.

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen ...

The researchers found that for infants aged 0 to 12 months, nirsevimab was associated with lower odds of RSV-related hospitalization, lower odds of intensive care unit admission, and lower odds of ...